Table 1.
The demographic and clinical profile of the 155 patients with gout
| Patient characteristic | Number (%) | Median | Range |
|---|---|---|---|
| Number of patients | 155 | ||
| Male/Female | 132/23 | ||
| Age (years) | 69.0 | 28.0–93.6 | |
| Height (cm) | 172 | 147–198 | |
| Weight (kg) | 83.0 | 42.5–139.0 | |
| BMI (kg m−2) | 27.6 | 17.4–46.4 | |
| Creatinine clearance (ml min−1)* | 37.6 | 6.0–130.4 | |
| Plasma urate concentration (mmol l−1) | 0.33 | 0.14–0.81 | |
| Allopurinol dose (mg day−1) | 300 | 50–400 | |
| Duration of gout (years)† | 11 | 0.2–>40 | |
| Tophi present | 20 (13) | ||
| Pharmacokinetic data | |||
| Number of blood samples | 1013 | ||
| Concentration (mg l−1) | 0.14–70.9 | ||
| Samples per patient | 1–30 | ||
| Number of occasions‡ | 1–5 | ||
| Concomitant medication | |||
| Diuretic§ | 72 (46) | ||
| Probenecid | 20 (13) |
SD, standard deviation; BMI, body mass index. *Estimated using the Cockcroft–Gault equation with total body weight; †Self-reported; ‡An occasion is classified as either (i) a new admission into hospital or (ii) commencement of a new concomitant medication and/or post a major event (e.g. surgery) §Including furosemide, thiazide diuretics and spironolactone.